What is Converge?
Converge is at the forefront of integrating Generative AI with biological data, transforming drug discovery and development. By harnessing the power of Large Language Models (LLMs) trained on the unique syntax of biological systems, Converge empowers biotech and pharmaceutical companies to predict biological outcomes, contextualize them with deeper insights, and generate novel molecular candidates. These advanced models transcend traditional computational methods, offering enhanced understanding of complex molecular interactions, signaling pathways, and disease mechanisms. This capability enables researchers to anticipate how compounds may interact with biological targets, thereby accelerating the identification of promising drug candidates.
How much funding has Converge raised?
Converge has raised a total of $30.5M across 2 funding rounds:
Angel/Seed
$5.5M
Series A
$25M
Angel/Seed (2024): $5.5M with participation from TLV Partners
Series A (2026): $25M led by TLV Partners, Saras Capital, Vintage Investment Partners, and Bessemer Venture Partners
Key Investors in Converge
TLV Partners
TLV Partners is an Israeli venture capital firm that invests in early-stage startups, collaborating with innovative entrepreneurs to create category-defining companies. With over $1 billion under management, the firm focuses on exceptional teams that are poised to shape the future across various sectors, including AI, healthcare, and application security.
Saras Capital
Saras Capital LLP is an appointed representative of Midmar Capital LLP, authorized and regulated by the Financial Conduct Authority for UK investment advisory and arranging activities. The company is registered in England and focuses exclusively on professional investors.
Vintage Investment Partners
Founded in 2003, Vintage Investment Partners is headquartered in Israel, with a strong footprint in U.S. and Europe, and over $3.6 billion in assets. The company's role is to be the company's Portfolios blue collar investor and trusted partner, who helps them succeed by delivering invaluable insights.
What's next for Converge?
The substantial enterprise-level financing positions Converge for accelerated growth and market expansion. This strategic investment will likely fuel further research and development into their AI-driven drug discovery platforms, enabling the company to scale its operations and deepen its impact within the pharmaceutical and biotechnology sectors. Expect Converge to forge new partnerships and enhance its LLM capabilities to address complex biological challenges, solidifying its position as a leader in AI-powered life sciences innovation.
See full Converge company page
